Home › Funds › Tetragon Partners GP Ltd › ACAD

Tetragon Partners GP Ltd position in ACAD

ACADIA PHARMACEUTICALS INC · Health Care

Tetragon Partners GP Ltd reported holding 167,875 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$4.2M, representing 0.69% of its reported portfolio and ranking #25 among its reported holdings. Tetragon Partners GP Ltd has disclosed ACAD holdings in 5 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)167.88K sh
Reported value held$4.25M
Portfolio Weight0.69%
First reportedQ1 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's ACAD position evolved

Tetragon Partners GP Ltd first disclosed a stake in ACAD in Q1 2025 at 107,000 shares (US$1.8M). The position peaked in Q2 2026 at 167,875 shares, worth US$4.2M. Across 5 filings, Tetragon Partners GP Ltd increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 167,875 shares valued at US$4.2M — an increase of 23,255 shares quarter over quarter.. Notable position changes include a 51% increase in Q2 2025 (shares fell 1% over the following quarter), a 47% trim in Q3 2025 (shares rose 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 107.00K $1.78M New
Q2 2025 161.40K $3.48M Add
Q3 2025 86.07K $1.84M Reduce
Q1 2026 144.62K $3.22M New
Q2 2026 167.88K $4.25M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACAD and 13F data

ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACAD

All ACAD fund holders →

FAQ

How long has Tetragon Partners GP Ltd held ACAD?

Tetragon Partners GP Ltd has disclosed ACAD holdings in 5 of the last 6 reported quarters, going back to Q1 2025.

What is Tetragon Partners GP Ltd's current position in ACAD?

As of Q2 2026, Tetragon Partners GP Ltd holds 167.88K shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $4.25M, representing 0.69% of its reported portfolio and ranking #25.

Has Tetragon Partners GP Ltd been buying or selling ACAD?

In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in ACAD. The position peaked in Q2 2026 at 167.88K shares.

Which other funds hold ACAD?

Other major institutional holders of ACAD include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Palo Alto Investors LP, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.